/Companies

Forge Therapeutics

2 known investors

Find your way into Forge Therapeutics

Sign up to see every warm intro you have to Forge Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Forge Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes. The company works on a pipeline of therapeutic programs based on this metalloenzyme-targeting approach.

Investors · 2

Funding

SEC filings, press & company announcements

$15M disclosed across 1 of 2 rounds · 2017

Source: company announcements and press reports — follow each round's link for the claim.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2016$150K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Forge Therapeutics do?
Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes. The company works on a pipeline of therapeutic programs based on this metalloenzyme-targeting approach.
Who are Forge Therapeutics's investors?
Forge Therapeutics's investors include MC Healthcare Ventures, Alexandria.
How much funding has Forge Therapeutics raised?
Forge Therapeutics has disclosed $15M raised across 1 of its 2 known rounds.